Phase 1b/2 study of liposomal annamycin (l-annamycin) in patients with previously treated metastatic soft-tissue sarcomas (ANNA-SARC)

Overview

Sponsor-declared trial summary

Key facts

Sponsor

Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

Participant type

Patients

Age range

18-64 years, 65+ years

Gender

Male and Female

Therapeutic area

Diseases [C] - Skin and Connective Tissue Diseases [C17], Diseases [C] - Neoplasms [C04]

Trial duration

14 Jan 2021 → 31 Mar 2025

Decision date (initial)

2025-01-11

Transition trial

Yes

Low-intervention

No

Rare-disease indication

No

Vulnerable population

No

Funding sources

Agencja Badań Medycznych (project ABM nr 2020/ABM/01/00016 - 00)

External identifiers

EU CT number

2024-517678-12-00

EudraCT number

2021-003762-13

Trial design

CTIS Part I — objectives, methods, condition coding

Main objective

Scope: Efficacy, Safety

Phase Ib: To establish the safety and tolerability of weekly dosed L-Annamycin in monotherapy in subjects with STS with metastases. Phase II: To determine the efficacy of L-Annamycin in subjects with STS with metastases.

Secondary objectives 1

1. Phase Ib/II: To determine further safety and tolerability for L-Annamycin, the pharmacokinetics of L-Annamycin and its metabolite (annamycinol) and efficacy.

Conditions and MedDRA coding

METASTATIC SOFT-TISSUE SARCOMAS AFTER FAILURE ON AT LEAST ONE SYSTEMIC THERAPY

Eligibility criteria

Principal inclusion / exclusion criteria as submitted by sponsor

Inclusion criteria 9

1. The subject is ≥18 years old at the time of signing informed consent.
2. The subject has an ECOG performance status ≤2 with an estimated life expectancy of greater than three months.
3. The subject has a pathologically confirmed diagnosis of STS (including the following pathological subtypes: liposarcoma, leiomyosarcoma, synovial sarcoma, angiosarcoma, undifferentiated pleomorphic sarcoma, myxofibrosarcoma, malignant peripheral nerve sheath tumour, malignant solitary fibrous tumour, and pleomorphic RMS), and documented metastases that are considered eligible for chemotherapy and not eligible for potentially curative surgical resection.
4. The subject must have measurable disease, defined as, at a minimum, one lesion that can be accurately measured in at least one dimension of >10 mm. Subjects with additional sites of disease are eligible.
5. The subject had prior anthracycline therapy (cumulative dose of ≤5000 mg/m2 ) for their disease and has shown the progression of the disease before study entry – for phase II trial maximum of three previous lines of therapy (adjuvant/neoadjuvant regimen is counted as one line of systemic treatment)
6. At least two weeks must have passed following treatment for their disease with chemotherapy, investigational therapy, targeted agents, biological agents, immune modulators, and any toxicities must have resolved to ≤ grade 1 or previous baseline levels no more than four weeks after completing therapy (except alopecia and polyneuropathy).
7. The subject must have adequate laboratory results, including the following: a. Absolute neutrophil count ≥ 1500/mL and platelets ≥100,000/mL b. Hemoglobin ≥8.0 g/dL c. Adequate renal function (The Cockcroft-Gault equation will be used to estimate creatinine clearance. This equation is as follows: Creatinine clearance in milliliters per minute= [140-age] x body weight [kg]/72 x plasma creatinine [mg/dL]; multiplied by 0.85 for women. By using this equation, adequate renal function will be deemed to be a creatinine clearance of greater than 60 mL/minute) d. Bilirubin ≤1.5 x ULN (unless due to Gilbert’s syndrome) e. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤ 2.5 × ULN (≤ 5 x ULN in subjects with liver metastases)
8. The subject is able to understand and sign the informed consent document, can communicate with the Investigator, and can understand and comply with the requirements of the protocol.
9. All subjects (men and women) agree to practise effective contraception during the entire study period and after discontinuing the study drug unless documentation of infertility exists. a. Sexually active, fertile women must use two effective forms of contraception (abstinence, intrauterine device, oral contraceptive, or double barrier device) from the time of informed consent and until at least six months after discontinuing the study drug. b. Sexually active men and their sexual partners must use effective contraceptive methods from the time of informed consent until at least six months after discontinuing the study drug.

Exclusion criteria 8

1. The subject has any condition that, in the opinion of the Investigator, places the subject at unacceptable risk if they were to participate in the study.
2. Metastases to the central nervous system
3. The subject has left ventricular ejection fraction (LVEF) <50%, valvular heart disease, or severe hypertension not controlled by medical therapy. Cardiac subjects with a New York Heart Association classification of 3 or 4 will be excluded, as will those with recent (≤ 6 months) myocardial infarction, unstable angina, or symptomatic congestive heart failure. The subject has a baseline QT/QTc interval >480 msec, a history of additional risk factors for torsade des pointes (e.g., heart failure, hypokalemia, family history of Long QT Syndrome) and use of concomitant medications that significantly prolong the QT/QTc interval.
4. The subject has clinically relevant serious comorbid medical conditions including, but not limited to active infection, known positive status for human immunodeficiency virus and/or active hepatitis B or C, cirrhosis, or psychiatric illness/social situations that would limit compliance with study requirements
5. The subject is pregnant, lactating, or not using adequate contraception
6. The subject has a known allergy to study drug or excipients.
7. The subject is required to use moderate or strong inhibitors and inducers of cytochrome P450 (CYP) family enzymes CYP3A and CYP2B and transporters that cannot be held three days before treatment and on the day of treatment.
8. Vaccinated with a live vaccine within 28 days prior to the first dose of the study drug. COVID-19 vaccination with mRNA or replication incompetent viral vector vaccines and annual inactivated influenza vaccines are permitted.

Endpoints

Primary and secondary outcome measures (English text)

Primary endpoints 2

1. Phase Ib: to determine the Recommended Phase 2 Dose (RP2D)
2. Phase II: to evaluate 3-month Progression-Free Survival (PFS).

Secondary endpoints 1

1. Phase Ib/II: Overall response rate (ORR): complete response (CR) and partial response (PR) as per revised Response Evaluation Criteria in Solid Tumours (RECIST) guidelines (Version 1.1), Clinical benefit (disease control) rate: CR + PR + stable disease (SD), Overall survival (OS), the potential for surgical resectability after L-Annamycin administration, pathological complete response (pCR) if surgical resection occurs and duration of response per RECIST guidelines (Version 1.1).

Investigational products

Investigational medicinal products (IMPs), comparators, placebo, auxiliary

Test 1

Sponsors and contacts

Sponsor organisations, regulatory contacts, third parties

Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

Sponsor organisation

Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

Address

Ul. Wilhelma Konrada Roentgena 5

City

Warsaw

Postcode

02-781

Country

Poland

Scientific contact point

Organisation

Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

Contact name

główny badacz

Public contact point

Organisation

Narodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy

Contact name

Dział Badań Klinicznych NIO-PIB

Locations

1 EU/EEA country · 1 investigational sites

By country

Investigational sites

Country notifications

Trial-start, recruitment-start, end and early-termination notifications submitted per Member State

Results and documents

Annex IV summary of results, Annex V layperson summary, and all documents registered in CTIS for this trial

Summary of results Art. 37(4) CTR

Layperson summary Annex V

Documents 7 files

Public protocol annexes, IB summaries, regulatory submissions and post-authorisation documents registered in CTIS.

Application history

1 submissions — initial application plus substantial / non-substantial modifications